{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"sCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Response was evaluated by appropriate imaging and myeloma serum/urine tests at the start of Cycle 1 and end of study, with response categorized per IMWG consensus criteria, as follows: stringent complete response (sCR) - CR criteria + normal free light chain (FLC) ratio + no clonal cells in bone marrow; CR - negative immunofixation on serum/urine + no soft tissue plasmacytomas + \\<5% plasma cells in bone marrow; very good partial response (VGPR) - serum/urine M-protein detectable by immunofixation but not electrophoresis OR ≥90% reduction in serum M-protein + urine \\<100 mg/24h; PR - ≥50% and ≥90% (or \\<200 mg/24h) reduction of serum + urine M-protein, respectively; progressive disease - increase of ≥25% serum and/or urine M-component, increase of \\>10 mg/dL in involved and uninvolved FLC levels, bone marrow plasma cells ≥10%, new or larger lesions, or corrected serum calcium \\>11.5 mg/dL or 2.65 mmol/L \\[Rajkumar et al. Blood 2011;117:4691-5; Durie et al. Leukemia 2006;20:1467-73\\].","groups":[{"description":"\"Late\" post-ASCT treatment (tremelimumab alone in Cycles 1-2, durvalumab alone in Cycles 3+)","id":"OG000","title":"Cohort 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects who received at least 1 dose of study treatment and underwent at least 1 post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Up to 14 months","title":"Number of Subjects With Best Response According to International Myeloma Working Group (IMWG) Consensus Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}